Brokerages expect that Luminex Co. (NASDAQ:LMNX) will announce earnings per share (EPS) of $0.08 for the current quarter, according to Zacks. Five analysts have made estimates for Luminex’s earnings, with the lowest EPS estimate coming in at $0.03 and the highest estimate coming in at $0.13. Luminex posted earnings of $0.25 per share in the same quarter last year, which indicates a negative year-over-year growth rate of 68%. The firm is scheduled to issue its next earnings report on Monday, October 29th.

According to Zacks, analysts expect that Luminex will report full year earnings of $0.56 per share for the current financial year, with EPS estimates ranging from $0.50 to $0.63. For the next year, analysts expect that the company will report earnings of $0.62 per share, with EPS estimates ranging from $0.41 to $0.74. Zacks’ earnings per share calculations are a mean average based on a survey of analysts that cover Luminex.

Luminex (NASDAQ:LMNX) last issued its quarterly earnings results on Monday, August 6th. The medical instruments supplier reported $0.15 earnings per share for the quarter, missing analysts’ consensus estimates of $0.19 by ($0.04). Luminex had a return on equity of 7.44% and a net margin of 10.57%. The business had revenue of $79.60 million for the quarter, compared to analysts’ expectations of $79.66 million. During the same period in the prior year, the company earned $0.26 EPS. The company’s revenue for the quarter was up 4.1% compared to the same quarter last year.

A number of brokerages have weighed in on LMNX. ValuEngine raised Luminex from a “buy” rating to a “strong-buy” rating in a research note on Thursday, July 19th. Jefferies Financial Group reissued a “hold” rating and set a $27.00 price target on shares of Luminex in a research note on Tuesday, August 7th. Zacks Investment Research raised Luminex from a “hold” rating to a “buy” rating and set a $34.00 price target on the stock in a research note on Monday, July 9th. BidaskClub lowered Luminex from a “strong-buy” rating to a “buy” rating in a research note on Saturday. Finally, Citigroup increased their price target on Luminex from $23.00 to $34.00 and gave the stock a “$33.58” rating in a research note on Monday, July 23rd. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the stock. Luminex has an average rating of “Hold” and an average target price of $28.60.

Shares of Luminex stock traded up $0.24 during trading hours on Monday, reaching $29.59. 282,900 shares of the company’s stock were exchanged, compared to its average volume of 321,099. Luminex has a 52-week low of $18.62 and a 52-week high of $35.37. The firm has a market cap of $1.31 billion, a PE ratio of 32.52, a P/E/G ratio of 3.39 and a beta of 0.25.

The company also recently announced a quarterly dividend, which will be paid on Friday, October 12th. Investors of record on Friday, September 21st will be given a $0.06 dividend. This represents a $0.24 annualized dividend and a dividend yield of 0.81%. The ex-dividend date of this dividend is Thursday, September 20th. Luminex’s dividend payout ratio (DPR) is currently 26.37%.

Several institutional investors and hedge funds have recently modified their holdings of LMNX. Raymond James Financial Services Advisors Inc. purchased a new position in shares of Luminex in the 2nd quarter worth $207,000. Crossmark Global Holdings Inc. purchased a new position in shares of Luminex in the 2nd quarter worth $214,000. Cubist Systematic Strategies LLC raised its position in shares of Luminex by 7,572.6% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 7,289 shares of the medical instruments supplier’s stock worth $215,000 after buying an additional 7,194 shares during the period. OppenheimerFunds Inc. purchased a new position in shares of Luminex in the 2nd quarter worth $231,000. Finally, Meeder Asset Management Inc. raised its position in shares of Luminex by 1,278.2% in the 2nd quarter. Meeder Asset Management Inc. now owns 8,076 shares of the medical instruments supplier’s stock worth $238,000 after buying an additional 7,490 shares during the period. 82.22% of the stock is currently owned by institutional investors and hedge funds.

Luminex Company Profile

Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; ARIES system, a sample to answer real-time PCR platform; ARIES M1 system, a single-module version of the ARIES System; and VERIGENE system, an automated multiplex-capable system.

Featured Story: Technical Analysis of Stocks and What It Means

Get a free copy of the Zacks research report on Luminex (LMNX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Luminex (NASDAQ:LMNX)

Receive News & Ratings for Luminex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex and related companies with MarketBeat.com's FREE daily email newsletter.